SCNX logo

SCIENTURE HOLDINGS INC

SCNXNASDAQ
πŸ† #5012 by market capEarnings Mar 29US Equity
$2.28β–Ό $0.16 (βˆ’6.45%)
Market closed Β· at close
πŸ””
Track SCNX
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.5%
7dβ–Ό 22.3%
14dβ–Ό 27.1%
30dβ–Ό 17.2%
ytdβ–Ό 82.0%
1yβ–Ό 83.1%
🏦Market Cap
$4M
Small Cap
πŸ“ˆRevenue Growth (YoY)
672.3%
High Growth
πŸ“ŠGross Margin
97.4%
High
πŸ’΅FCF Margin
426.4%
Strong
βš–οΈP/S Ratio
4.1x
Fair
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$2.00 – $2.35
52-Week Range
$2.00 – $18.75
Volume (shares)
29,856
Avg Volume (shares)
β€”
Shares Outstanding
1.6M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
$431,609
Last Q Revenue
$343,639
P/E Ratio
β€”
P/S Ratio
4.1x
EPS (TTM)
$-8.63
Dividend Yield
53.72%
Dilution (1yr)
+1653.9%
SCNX logo

SCIENTURE HOLDINGS INC

SCNX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$432Kβ–² +215.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
76.8%β–² +1647.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$16Mβ–² +10.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$13Mβ–Ό βˆ’6.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
6.1Mβ–² +1653.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7Mβ–² +$10M YoY
StockOtter Β· stockotter.space

About SCIENTURE HOLDINGS INC

As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Nov 2026

Latest News & Updates

GlobeNewsWireΒ·6d ago

SCIENTURE Reports Q3 2026 Results with Approximately 265% Sequential Revenue Growth Driven by the Commercial Launch of REZENOPYβ„’

Q3 2026 Revenue Increased Approximately 113% Year-Over-Year to $1.25 Million Arbli β„’ generated approximately $330,000 and $730,000 of Net Product Revenue for Q3 2026 and the first nine months of 2026 respectively Initial

Seeking AlphaΒ·25d ago

Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript

Scienture Holdings, Inc. (SCNX) Shareholder/Analyst Call Prepared Remarks Transcript

GlobeNewsWireΒ·Oct 22

SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027

Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli β„’ Growth and the Commercial Launch of REZENOPY β„’

GlobeNewsWireΒ·Oct 13

SCIENTURE Reports Approximately $1.22 Million in Unaudited Preliminary Q3 2026 Revenue, Achieving 256% Sequential Growth

Continued Arbli β„’ sales growth, combined with REZENOPY β„’ commercial launch in August 2026 and initial wholesale shipments, drives significant sequential revenue growth

GlobeNewsWireΒ·Oct 2

SCIENTURE Announces Arbliβ„’ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals

Major Institutional Formulary Win Expands Arbli β„’ 's Presence in Pediatric Care as Wholesale Orders Continue to Increase Sequentially

GlobeNewsWireΒ·Sep 30

Scienture Holdings, Inc. Announces Reverse Stock Split

COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (β€œScienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to